Healthcare / Medical Instruments & SuppliesKuala Lumpur
$0.08
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-76.1M · quality 54.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$62M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-37.7%
↓Gross Margin
-21.9%
↓Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
-38.7%
FCF CAGR
—
FCF margin
-25.7%
FCF / Net income
0.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $98.9M · net income $-81.6M · FCF $-25.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $98.9M | $98.9M | $84.7M | $261.6M | $700.3M |
| Net Income | $-81.6M | $-81.6M | $-26.1M | $-122.1M | $221.0M |
| EBITDA | $-65.1M | $-65.1M | $-7.0M | $-96.1M | $300.8M |
| EPS | -0.11 | -0.11 | -0.04 | -0.21 | 0.39 |
| Gross Margin | -21.9% | -21.9% | -24.9% | -29.7% | 40.7% |
| Operating Margin | -34.0% | -34.0% | -29.0% | -34.4% | 37.7% |
| Net Margin | -82.5% | -82.5% | -30.8% | -46.7% | 31.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.17 | 0.17 | 0.04 |
| Current Ratio | 1.14 | 1.14 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-25.4M | $-25.4M | $-76.1M | $-103.4M | $59.6M |
| Returns | |||||
| ROE | -37.7% | -37.7% | -9.2% | -33.3% | 45.5% |
| Valuation | |||||
| P/E | — | — | — | — | 2.64 |
| EV/EBITDA | — | — | — | — | 1.60 |
| P/B | 0.27 | 0.27 | 0.69 | 0.73 | 1.20 |
| Growth & Yield | |||||
| Revenue Growth | 16.8% | 16.8% | -67.6% | -62.7% | — |
| EPS Growth | -163.4% | -163.4% | 80.2% | -154.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-46.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.04 → -0.11
Residual
-46.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.